Quanticate, a global data-focused clinical research organisation, has introduced QVigilance to offer dedicated pharmacovigilance (PV) and risk management services, it was reported yesterday.
The service will concentrate on supporting small and mid-size companies transitioning from clinical trials to post-marketing and establishing compliant PV systems. Quanticate offers the full range of global PV services to clinical trial sponsors and market authorisation holders (MAHs) in the pharmaceutical, biopharma and medical device sectors, including case processing and reporting, global and local literature screening, aggregate production and reporting, signal and risk management, regulatory intelligence and guidance for regional markets.
The company is also offering EU-specific support including EudraVigilance registration and management, creation and maintenance of the Pharmacovigilance System Master File and offering an EU Qualified Person responsible for Pharmacovigilance to support and manage client portfolios.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project